Enlivex Ltd ENLV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.69
- Day Range
- $1.53–1.71
- 52-Week Range
- $1.53–31.50
- Bid/Ask
- $1.59 / $1.64
- Shares Outstanding
- 16.83M
- Market Cap
- $26.59M
- Volume/Avg
- 342,396 / 167,817
Key Statistics
- Price/Earnings (Normalized)
- 0.16
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 34
- Website
- https://www.enlivex.com
Valuation
|
Metric
|
ENLV
|
|---|---|
Price/Earnings (Normalized) | 0.16 |
Price/Book Value | 0.01 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ENLV
Financial Strength
|
Metric
|
ENLV
|
|---|---|
Quick Ratio | 0.69 |
Current Ratio | 193.24 |
Interest Coverage | — |
Quick Ratio
ENLV
Profitability
|
Metric
|
ENLV
|
|---|---|
Return on Assets (Normalized) | −201.70% |
Return on Equity (Normalized) | −242.39% |
Return on Invested Capital (Normalized) | −242.19% |
Return on Assets
ENLV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|nvF<%n | LOCK|YP>dR | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#CQjts | LOCK|Xd$@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|Hqz>>< | LOCK|@#f | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!!$D@?h | LOCK|npl#$ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%^V>!s% | LOCK|z^ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^P@bt^@ | LOCK|xBXQ | $31B | |||
| Moderna Inc
MRNA
| LOCK|#<&s@q | LOCK|@? | $25B | |||
| Incyte Corp
INCY
| LOCK|&$@>LQl | LOCK|z?> | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|z<f@Wt | LOCK|rK | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$nkHyS | LOCK|fc | $16B |
United States